Original Research
Saving money in the European healthcare systems with biosimilars
Published in: Volume 1 / Year 2012 / Issue 3-4
Author(s): 1 Robert Haustein, 2 Christoph de Millas, 3 Ariane Höer, MD, 4 Professor Bertram Häussler, MD
Page: 120-6
Author(s): 1 Robert Haustein, 2 Christoph de Millas, 3 Ariane Höer, MD, 4 Professor Bertram Häussler, MD
Page: 120-6
Introduction: The use of biotechnological manufactured drugs, or biologicals, has increased massively over the past few years. Used especially in the treatment of cancer and other severe diseases, biologicals incur high… Read More »
European prescribers’ attitudes and beliefs on biologicals prescribing and automatic substitution
Published in: Volume 9 / Year 2020 / Issue 3
Author(s): Madelaine A Feldman, MD, FACR, Michael S Reilly, Esq
Page: 116-24
Author(s): Madelaine A Feldman, MD, FACR, Michael S Reilly, Esq
Page: 116-24
Introduction: The European Union (EU) and the European Medicines Agency (EMA) have led the development of a regulatory framework for biosimilars since 2004. By end of December 2019, 64 biosimilars… Read More »